Nectar Lifesciences Limited (NECLIFE.BO)
INR 44.02
(0.0%)
INR 44.02
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 1.56 Billion INR | 159.56% |
| 2022 | 863.08 Million INR | -61.09% |
| 2021 | 1.7 Billion INR | 53.61% |
| 2020 | 790.29 Million INR | -48.0% |
| 2019 | 2.17 Billion INR | -9.69% |
| 2018 | 2.09 Billion INR | -2.27% |
| 2017 | 2.15 Billion INR | 3.35% |
| 2016 | 2.47 Billion INR | -0.15% |
| 2015 | 2.44 Billion INR | -15.07% |
| 2014 | 2.49 Billion INR | -2.07% |
| 2013 | 2.5 Billion INR | -15.26% |
| 2012 | 2.95 Billion INR | 24.46% |
| 2011 | 2.36 Billion INR | -1.29% |
| 2010 | 2.4 Billion INR | 18.18% |
| 2009 | 2.14 Billion INR | 46.33% |
| 2008 | 1.39 Billion INR | -7.42% |
| 2007 | 1.5 Billion INR | 73.68% |
| 2006 | 865.43 Million INR | 10.74% |
| 2005 | 781.51 Million INR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 398.03 Million INR | -19.25% |
| 2023 Q2 | 374.73 Million INR | 4.05% |
| 2023 FY | - INR | 159.56% |
| 2023 Q1 | 360.13 Million INR | 3049.98% |
| 2023 Q4 | 485.03 Million INR | 13.67% |
| 2023 Q3 | 426.7 Million INR | 13.87% |
| 2022 Q4 | -12.2 Million INR | -108.31% |
| 2022 FY | - INR | -61.09% |
| 2022 Q1 | 421.72 Million INR | 34.33% |
| 2022 Q2 | 33.11 Million INR | -92.15% |
| 2022 Q3 | 146.85 Million INR | 343.5% |
| 2021 Q4 | 313.95 Million INR | -33.37% |
| 2021 FY | - INR | 53.61% |
| 2021 Q3 | 471.19 Million INR | 44.74% |
| 2021 Q2 | 325.54 Million INR | -19.64% |
| 2021 Q1 | 405.12 Million INR | 289.87% |
| 2020 Q4 | -213.37 Million INR | -163.86% |
| 2020 Q1 | 171.73 Million INR | -14.24% |
| 2020 Q3 | 334.13 Million INR | 4.41% |
| 2020 Q2 | 320.01 Million INR | 86.34% |
| 2020 FY | - INR | -48.0% |
| 2019 Q1 | 641.2 Million INR | 299.68% |
| 2019 Q3 | 565.68 Million INR | 15.34% |
| 2019 FY | - INR | -9.69% |
| 2019 Q4 | 200.25 Million INR | -64.6% |
| 2019 Q2 | 490.43 Million INR | -23.51% |
| 2018 Q3 | 667.9 Million INR | 1.46% |
| 2018 Q1 | 614.66 Million INR | 0.0% |
| 2018 Q4 | 160.43 Million INR | -75.98% |
| 2018 FY | - INR | -2.27% |
| 2018 Q2 | 658.27 Million INR | 7.09% |
| 2017 FY | - INR | 3.35% |
| 2016 FY | - INR | -0.15% |
| 2015 Q3 | - INR | 0.0% |
| 2015 FY | - INR | -15.07% |
| 2014 FY | - INR | -2.07% |
| 2014 Q3 | - INR | 0.0% |
| 2013 FY | - INR | -15.26% |
| 2012 FY | - INR | 24.46% |
| 2011 FY | - INR | -1.29% |
| 2010 FY | - INR | 18.18% |
| 2009 FY | - INR | 46.33% |
| 2008 FY | - INR | -7.42% |
| 2007 FY | - INR | 73.68% |
| 2006 FY | - INR | 10.74% |
| 2005 FY | - INR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Ajanta Pharma Limited | 12.56 Billion INR | 87.555% |
| Amrutanjan Health Care Limited | 682.53 Million INR | -129.114% |
| Sigachi Industries Limited | 883.39 Million INR | -77.02% |
| Bal Pharma Limited | 345.59 Million INR | -352.496% |
| Ind-Swift Laboratories Limited | 6.86 Billion INR | 77.21% |
| Medico Remedies Limited | 150.37 Million INR | -939.906% |
| Lasa Supergenerics Limited | -65.08 Million INR | 2502.873% |
| Venus Remedies Limited | 711.8 Million INR | -119.695% |
| Sun Pharma Advanced Research Company Limited | -3.73 Billion INR | 141.91% |
| Alpa Laboratories Limited | 86.12 Million INR | -1715.679% |
| Shilpa Medicare Limited | 2.58 Billion INR | 39.575% |
| Aarti Drugs Limited | 3.24 Billion INR | 51.863% |
| Lupin Limited | 36.96 Billion INR | 95.77% |
| Aurobindo Pharma Limited | 61.78 Billion INR | 97.469% |
| Zydus Lifesciences Limited | 56.22 Billion INR | 97.219% |
| Windlas Biotech Limited | 781.72 Million INR | -100.045% |
| Suven Life Sciences Limited | -992.78 Million INR | 257.516% |
| Eris Lifesciences Limited | 6.98 Billion INR | 77.617% |
| Valiant Laboratories Limited | 12.73 Million INR | -12175.61% |
| J. B. Chemicals & Pharmaceuticals Limited | 9.33 Billion INR | 83.248% |
| Solara Active Pharma Sciences Limited | -2.82 Billion INR | 155.416% |
| Ipca Laboratories Limited | 13.29 Billion INR | 88.242% |
| Bliss GVS Pharma Limited | 1.47 Billion INR | -5.731% |
| Achyut Healthcare Limited | 524 Thousand INR | -298333.206% |
| Sun Pharmaceutical Industries Limited | 138.36 Billion INR | 98.87% |
| Bajaj HealthCare Limited | 444.51 Million INR | -251.796% |
| RPG Life Sciences Limited | 1.28 Billion INR | -22.028% |
| Mankind Pharma Limited | 28.09 Billion INR | 94.434% |
| Laurus Labs Limited | 8 Billion INR | 80.467% |
| Piramal Pharma Limited | 13.05 Billion INR | 88.022% |
| Syncom Formulations (India) Limited | 430.27 Million INR | -263.439% |
| Torrent Pharmaceuticals Limited | 35 Billion INR | 95.533% |
| Alembic Pharmaceuticals Limited | 9.61 Billion INR | 83.739% |
| Glenmark Pharmaceuticals Limited | 11.34 Billion INR | 86.214% |
| Unichem Laboratories Limited | 742.35 Million INR | -110.652% |
| Sequent Scientific Limited | 549.8 Million INR | -184.429% |
| Novartis India Limited | 1.26 Billion INR | -23.201% |
| Wanbury Limited | 985.49 Million INR | -58.681% |
| Suven Pharmaceuticals Limited | 4.67 Billion INR | 66.566% |
| Wockhardt Limited | 1.08 Billion INR | -44.795% |
| Themis Medicare Limited | 562.6 Million INR | -177.954% |
| Jagsonpal Pharmaceuticals Limited | 323.46 Million INR | -383.457% |
| Jubilant Pharmova Limited | 8 Billion INR | 80.467% |
| Glenmark Life Sciences Limited | 6.86 Billion INR | 77.214% |
| Dr. Reddy's Laboratories Limited | 88.27 Billion INR | 98.229% |
| Divi's Laboratories Limited | 25.43 Billion INR | 93.851% |
| NATCO Pharma Limited | 18.79 Billion INR | 91.68% |
| Gufic Biosciences Limited | 1.48 Billion INR | -5.627% |
| IOL Chemicals and Pharmaceuticals Limited | 2.6 Billion INR | 40.007% |
| Ind-Swift Limited | 1.06 Billion INR | -46.826% |
| Procter & Gamble Health Limited | 3.01 Billion INR | 48.123% |
| FDC Limited | 4.4 Billion INR | 64.473% |
| Krebs Biochemicals & Industries Limited | -82.72 Million INR | 1990.302% |
| Granules India Limited | 8.6 Billion INR | 81.824% |
| Medicamen Biotech Limited | 245.66 Million INR | -536.567% |
| Alkem Laboratories Limited | 24.19 Billion INR | 93.537% |
| AstraZeneca Pharma India Limited | 2.35 Billion INR | 33.648% |
| Biofil Chemicals and Pharmaceuticals Limited | 13.06 Million INR | -11872.056% |
| Brooks Laboratories Limited | 41.72 Million INR | -3647.58% |
| Megasoft Limited | 284.73 Million INR | -449.217% |
| ZIM Laboratories Limited | 462.09 Million INR | -238.412% |
| Strides Pharma Science Limited | 3.76 Billion INR | 58.462% |
| Neuland Laboratories Limited | 4.74 Billion INR | 67.066% |
| Morepen Laboratories Limited | 1.72 Billion INR | 9.396% |
| Hikal Limited | 2.69 Billion INR | 41.915% |
| Indoco Remedies Limited | 2.64 Billion INR | 40.923% |
| Aarti Pharmalabs Limited | 3.9 Billion INR | 59.999% |
| Kilitch Drugs (India) Limited | 287.42 Million INR | -444.069% |
| Mangalam Drugs & Organics Limited | 174.94 Million INR | -793.87% |
| Hester Biosciences Limited | 539.47 Million INR | -189.875% |